At this time, FDA has not concluded that Actos increases the risk of bladder cancer.
Its review is ongoing, and the Agency will update the public when it has additional information.

FDA Drug Safety Communication: Ongoing Safety Review of Actos (pioglitazone) and Potential Increased Risk of Bladder Cancer After Two Years Exposure


by internalmedicine | 2010-09-21 14:59 | 糖尿病・肥満  

<< 肥満ダイエット中、毎日ミルク・... “less is more”:... >>